Table 2.

Multivariable regression analyses of key clinical variables with cell type-specific signatures in pooled PRESS and GENISOS datasets

	Coefficient	95% CI	P value
CD8 T cell*
Disease duration	−0.026	−0.042 to −0.009	<0.01
mRSS	0.006	−0.002 to 0.014	0.12
FVC % pred	−0.001	−0.005 to 0.002	0.54
No immunosuppression	0.095	−0.058 to 0.249	0.22
CD4 T cell*
Disease duration	−0.02	−0.034 to −0.006	<0.01
mRSS	0.004	−0.003 to 0.010	0.25
FVC % pred	−0.001	−0.004 to 0.002	0.49
No immunosuppression	0.06	−0.069 to 0.190	0.36
NK cell*
Disease duration	−0.019	−0.031 to −0.007	<0.01
mRSS	0.004	−0.001 to 0.010	0.12
FVC % pred	−0.001	−0.004 to 0.001	0.39
No immunosuppression	0.086	−0.026 to 0.197	0.13
B cell*
Disease duration	−0.023	−0.037 to −0.009	<0.01
mRSS	0.002	−0.005 to 0.009	0.56
FVC % pred	−0.001	−0.004 to 0.002	0.5
No immunosuppression	−0.014	−0.146 to 0.119	0.84
M1 macrophage*
Disease duration	−0.013	−0.030 to 0.004	0.13
mRSS	0.013	0.005 to 0.021	<0.01
FVC % pred	−0.002	−0.005 to 0.002	0.36
No immunosuppression	0.04	−0.119 to 0.199	0.62
M2 macrophage*
Disease duration	−0.001	−0.014 to 0.012	0.91
mRSS	0.014	0.007 to 0.020	<0.01
FVC % pred	−0.001	−0.003 to 0.002	0.61
No immunosuppression	0.005	−0.117 to 0.127	0.94
Fibroblast*
Disease duration	0.001	−0.015 to 0.016	0.93
mRSS	0.016	0.008 to 0.023	<0.01
FVC % pred	0.001	−0.002 to 0.004	0.57
No immunosuppression	0.028	−0.119 to 0.174	0.71

^*Cell type transcript signature used as the dependent variable in the multivariable model. FVC, forced vital capacity; GENISOS, Genetics versus Environment in Scleroderma Outcomes Study; mRSS, modified Rodnan Skin Score; NK, natural killer; PRESS, Prospective Registry for Early Systemic Sclerosis.